Nimer Assy

Summary

Country: Israel

Publications

  1. ncbi Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid
    Nimer Assy
    Section of Hepatology, University of Manitoba, Winnipeg, Manitoba Canada, and Liver Unit, Sieff Hospital, Safed, Israel
    Transplantation 83:1571-6. 2007
  2. ncbi Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers
    Nimer Assy
    Liver Unit, Ziv Medical Center, Zefat 13100, Israel
    World J Gastroenterol 15:3025-31. 2009
  3. ncbi Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients
    Assy Nimer
    Department of Liver, Ziv Medical Center, Safed 13100, Israel
    World J Gastroenterol 18:800-5. 2012
  4. ncbi Soft drink consumption linked with fatty liver in the absence of traditional risk factors
    Nimer Assy
    Liver Unit, Ziv Medical Center, Safed, Israel
    Can J Gastroenterol 22:811-6. 2008
  5. ncbi Characteristics of common solid liver lesions and recommendations for diagnostic workup
    Nimer Assy
    Liver Unit, Ziv Medical Center, Zefat 13100, Israel
    World J Gastroenterol 15:3217-27. 2009
  6. ncbi Reactivation versus primary CMV infection after splenectomy in immunocompetent patients
    N Assy
    Sieff Government Hospital Liver Unit, Safed, Israel
    Dig Dis Sci 52:3477-9. 2007
  7. ncbi The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure
    Nimer Assy
    Liver Clinic, Sieff Government Hospital, P.O.B. 1008, Safed 13100, Israel
    Dig Dis Sci 52:3507-10. 2007
  8. ncbi Olive oil consumption and non-alcoholic fatty liver disease
    Nimer Assy
    Liver Unit, Ziv Medical Centre, Safed, Israel
    World J Gastroenterol 15:1809-15. 2009
  9. ncbi The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis
    Nimer Assy
    Liver Clinic, Sieff Government Hospital, P O B 1008, Safed 13100, Israel
    Dig Dis Sci 52:1187-93. 2007
  10. ncbi Presence of coronary plaques in patients with nonalcoholic fatty liver disease
    Nimer Assy
    Liver Unit, Ziv Medical Centre, Box 1008, Safed 13100, Israel
    Radiology 254:393-400. 2010

Collaborators

Detail Information

Publications27

  1. ncbi Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid
    Nimer Assy
    Section of Hepatology, University of Manitoba, Winnipeg, Manitoba Canada, and Liver Unit, Sieff Hospital, Safed, Israel
    Transplantation 83:1571-6. 2007
    ..There are two goals, to determine: 1) whether TIW is frequently associated with rejection; and 2) whether UDCA decreases the risk of liver disease (both rejection and recurrence) after TIW...
  2. ncbi Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers
    Nimer Assy
    Liver Unit, Ziv Medical Center, Zefat 13100, Israel
    World J Gastroenterol 15:3025-31. 2009
    ..To determine whether new cut-off values for alanine aminotransferase (ALT) and baseline hepatitis B virus (HBV) DNA levels better differentiate HBeAg(-) chronic hepatitis B (CHB) patients from inactive chronic carriers...
  3. ncbi Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients
    Assy Nimer
    Department of Liver, Ziv Medical Center, Safed 13100, Israel
    World J Gastroenterol 18:800-5. 2012
    ..To examine whether vitamin D improved viral response and predicted treatment outcome in patients with hepatitis C virus (HCV) genotype 2-3...
  4. ncbi Soft drink consumption linked with fatty liver in the absence of traditional risk factors
    Nimer Assy
    Liver Unit, Ziv Medical Center, Safed, Israel
    Can J Gastroenterol 22:811-6. 2008
    ..Little is known about dietary habits and their relationships with liver disease in nonalcoholic fatty liver disease (NAFLD) patients, particularly in the absence of obesity, diabetes or hyperlipidemia...
  5. ncbi Characteristics of common solid liver lesions and recommendations for diagnostic workup
    Nimer Assy
    Liver Unit, Ziv Medical Center, Zefat 13100, Israel
    World J Gastroenterol 15:3217-27. 2009
    ..If the patient is known to have a primary malignancy and the lesion was found at tumor staging or follow up, histology is required only when the nature of the liver lesion is doubtful...
  6. ncbi Reactivation versus primary CMV infection after splenectomy in immunocompetent patients
    N Assy
    Sieff Government Hospital Liver Unit, Safed, Israel
    Dig Dis Sci 52:3477-9. 2007
    ..Splenectomy changed the immunological defense against the virus and brought the infection to nearly fulminant scale...
  7. ncbi The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure
    Nimer Assy
    Liver Clinic, Sieff Government Hospital, P.O.B. 1008, Safed 13100, Israel
    Dig Dis Sci 52:3507-10. 2007
  8. ncbi Olive oil consumption and non-alcoholic fatty liver disease
    Nimer Assy
    Liver Unit, Ziv Medical Centre, Safed, Israel
    World J Gastroenterol 15:1809-15. 2009
    ....
  9. ncbi The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis
    Nimer Assy
    Liver Clinic, Sieff Government Hospital, P O B 1008, Safed 13100, Israel
    Dig Dis Sci 52:1187-93. 2007
    ..3%+/-6.8%, versus 34.2%+/-7.2% in untreated cirrhotic controls; P<0.01) but unchanged in the enoxaparin group. We conclude that aspirin and enoxaparin hold promise as a useful therapy for patients with extensive fibrosis...
  10. ncbi Presence of coronary plaques in patients with nonalcoholic fatty liver disease
    Nimer Assy
    Liver Unit, Ziv Medical Centre, Box 1008, Safed 13100, Israel
    Radiology 254:393-400. 2010
    ..To evaluate the relationship between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) and to define determinants of CAD in patients with or without metabolic syndrome...
  11. ncbi Nutritional recommendations for patients with non-alcoholic fatty liver diseases
    Nimer Assy
    Liver Unit, Faculty of Medicine, Ziv Medical Center, Safed 13100, Israel
    World J Gastroenterol 17:3375-6. 2011
    ..Among the dietary constituents, combination of vitamin D, vitamin E, and omega-3 fatty acids shows promise for the treatment of NAFLD...
  12. ncbi The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
    Nimer Assy
    Liver Unit, Sieff Hospital, Safed, Israel
    BMC Gastroenterol 6:39. 2006
    ..Patients with compensated Child-A cirrhosis have sub clinical hypovolemia and diuretic treatment could result in renal impairment...
  13. ncbi Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease
    Nimer Assy
    Liver Unit, Sieff Government Hospital, POB 1008, Safed 13100, Israel
    World J Gastroenterol 12:4369-76. 2006
    ....
  14. ncbi Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases
    N Assy
    Liver Unit, Sieff Government Hospital, Safed 13100, Israel
    World J Gastroenterol 11:5834-9. 2005
    ..To evaluate the prevalence of genetic and acquired prothrombotic risk factors and their association with the extent of fibrosis and fatty infiltration in patients with non-alcoholic fatty liver disease (NAFLD)...
  15. ncbi Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction
    Nimer Assy
    Liver Unit, Ziv Medical Center, Safed 13100, Israel
    J Hepatol 49:34-42. 2008
    ..Previous studies reported decreased serum IGF-1 levels in cirrhosis. We aimed to correlate GH-stimulated IGF-1 responses with both MELD and Child-Pugh scores and determine the impact of portal hypertension and nutrition on IGF-1 responses...
  16. ncbi Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH)
    Osamah Hussein
    Department of Internal Medicine A, Sieff Government Hospital, Safed, Israel
    Dig Dis Sci 52:2512-9. 2007
    ..In conclusion, in obese patients with NASH, liver fibrosis and inflammation improved after therapy with orlistat...
  17. ncbi Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome
    Ali Abid
    Liver Unit, Ziv Medical Center, Safed, Israel
    J Hepatol 51:918-24. 2009
    ..We aimed to assess the association between consumption of soft drinks and fatty liver in patients with or without metabolic syndrome...
  18. ncbi Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients
    Saif Abu-Mouch
    Liver Unit, Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera 38100, Israel
    World J Gastroenterol 17:5184-90. 2011
    ..To determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy...
  19. ncbi Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation
    Osamah Hussein
    Internal Medicine A, Sieff Government Hospital, Safed, Israel
    Dig Dis Sci 47:1926-31. 2002
    ..In conclusion, liver regeneration is not altered in patients with nonalcoholic steatohepatitis, suggesting that the delayed postoperative liver failure seen in these patients may be related to another mechanism...
  20. ncbi Are chronic hepatitis C viral infections more benign in patients with hemophilia?
    Nimer Assy
    Liver Disease Unit, Department of Medicine and Liver Unit, Ziv Medical Center, Technion Institute, Haifa, Israel
    Am J Gastroenterol 102:1672-6. 2007
    ..Cirrhosis is associated with thromboses of the intrahepatic vasculature. This raises the possibility that HCV infections in hemophiliacs may differ from those in non-hemophiliacs..
  21. ncbi Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats
    Osamah Hussein
    Internal Medicine A, Sieff Government Hospital, PO Box 1008, Safed 13100, Israel
    World J Gastroenterol 13:361-8. 2007
    ..To evaluate the effects of different types of dietary fats on the hepatic lipid content and oxidative stress parameters in rat liver with experimental non-alcoholic fatty liver disease (NAFLD)...
  22. ncbi First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study
    Nimer Assy
    Liver Unit, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Gastroenterol 46:e27-30. 2012
    ..To evaluate the efficacy and toxicity of capecitabine with irinotecan as first-line treatment in metastatic colorectal cancer...
  23. ncbi Severe cholestatic jaundice in the elderly induced by low-dose amiodarone
    Nimer Assy
    Sieff Government Hospital Liver Clinic, Safed, Israel
    Dig Dis Sci 49:450-2. 2004
  24. ncbi Plasmodium and Borrelia co-infection
    Dan Miron
    Infectious Disease Consultation Service, Sieff Hospital, Safed
    J Travel Med 11:115-6. 2004
  25. ncbi Peginterferon and ribavirin for hepatitis C
    Nimer Assy
    N Engl J Med 356:1269; author reply 1271. 2007
  26. ncbi Day-case liver biopsy: a prospective evaluation of 300 cases
    Nimer Assy
    Am J Gastroenterol 102:2611-2. 2007
  27. ncbi Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis
    Nimer Assy
    Gut 56:443-4. 2007